Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients : Initial experience at a single center in Madrid, Spain
© 2020 Wiley Periodicals LLC..
BACKGROUND: Which are the consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant (LT) recipients?.
METHODS: We attempted to address this question by reviewing our single-center experience during the first 2 months of the pandemics at a high incidence area.
RESULTS: Nineteen adult patients (5 females) were diagnosed by May 5, 2020. Median age was 58 (range 55-72), and median follow-up since transplantation was 83 (range 20-183) months. Cough (84.2%), fever (57.9%), and dyspnea (47.4%) were the most common symptoms. Thirteen patients (68.4%) had pneumonia in x-ray/CT scan. Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon β in 2 cases each. Immunomodulatory therapy with tocilizumab was used in 2 patients. Immunosuppression (IS) was halted in one patient and modified in only other two due to potential drug interactions. Five (26.3%) patients were managed as outpatient. Two patients (10.5%) died, 10 (52.6%) were discharged home, and 2 (10.5%) were still hospitalized after a median follow-up of 41 days from the onset of symptoms. Baseline IS regimen remained unchanged in all surviving recipients, with good liver function.
CONCLUSIONS: Our preliminary experience shows a broad spectrum of disease severity in LT patients with COVID-19, with a favorable outcome in most of them without needing to modify baseline IS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Transplant infectious disease : an official journal of the Transplantation Society - 22(2020), 5 vom: 15. Okt., Seite e13372 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loinaz, Carmelo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2020 Date Revised 11.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/tid.13372 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311411983 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311411983 | ||
| 003 | DE-627 | ||
| 005 | 20231225142211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/tid.13372 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311411983 | ||
| 035 | |a (NLM)32562561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loinaz, Carmelo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients |b Initial experience at a single center in Madrid, Spain |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Which are the consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant (LT) recipients? | ||
| 520 | |a METHODS: We attempted to address this question by reviewing our single-center experience during the first 2 months of the pandemics at a high incidence area | ||
| 520 | |a RESULTS: Nineteen adult patients (5 females) were diagnosed by May 5, 2020. Median age was 58 (range 55-72), and median follow-up since transplantation was 83 (range 20-183) months. Cough (84.2%), fever (57.9%), and dyspnea (47.4%) were the most common symptoms. Thirteen patients (68.4%) had pneumonia in x-ray/CT scan. Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon β in 2 cases each. Immunomodulatory therapy with tocilizumab was used in 2 patients. Immunosuppression (IS) was halted in one patient and modified in only other two due to potential drug interactions. Five (26.3%) patients were managed as outpatient. Two patients (10.5%) died, 10 (52.6%) were discharged home, and 2 (10.5%) were still hospitalized after a median follow-up of 41 days from the onset of symptoms. Baseline IS regimen remained unchanged in all surviving recipients, with good liver function | ||
| 520 | |a CONCLUSIONS: Our preliminary experience shows a broad spectrum of disease severity in LT patients with COVID-19, with a favorable outcome in most of them without needing to modify baseline IS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a liver transplant | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Marcacuzco, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Caso, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Cambra, Félix |e verfasserin |4 aut | |
| 700 | 1 | |a San Juan, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Justo, Iago |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sesma, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Manrique, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Jacoiste Asín, María Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Folgueira, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Lumbreras, Carlos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant infectious disease : an official journal of the Transplantation Society |d 1999 |g 22(2020), 5 vom: 15. Okt., Seite e13372 |w (DE-627)NLM113005482 |x 1399-3062 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:5 |g day:15 |g month:10 |g pages:e13372 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/tid.13372 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 5 |b 15 |c 10 |h e13372 | ||